Neurizon to Present NUZ-001 Science in HEALEY ALS Platform Trial Webinar

Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.

Neurizon Therapeutics will participate in a community webinar hosted by the Healey & AMG Center for ALS, titled “HEALEY ALS Platform Trial Regimen I Science with Neurizon,” held on 19 March 2026 ET. The session will provide a high-level overview of the scientific rationale behind NUZ-001, which is being evaluated as Regimen I in an ongoing Phase 2/3 clinical trial for ALS.

The webinar appearance underscores Neurizon’s efforts to engage the ALS community and highlight progress of its lead asset within the HEALEY ALS Platform Trial. By showcasing the science and clinical strategy for NUZ-001, the company reinforces its positioning as an emerging player in ALS drug development and signals continued momentum in advancing its pipeline for patients with neurodegenerative disorders.

The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, with a primary emphasis on amyotrophic lateral sclerosis, the most common form of motor neurone disease. Its lead investigational candidate, NUZ-001, is being advanced through international collaborations and rigorous clinical programs, with the company aiming to accelerate patient access to effective ALS therapies and assess broader neurodegenerative applications.

Average Trading Volume: 637,417

Technical Sentiment Signal: Sell

Current Market Cap: A$57.29M

Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.